<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739412</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000086</org_study_id>
    <nct_id>NCT02739412</nct_id>
  </id_info>
  <brief_title>Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients</brief_title>
  <official_title>Efficacy of Low Dose, Subcutaneous Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to study if very low dose IL-2, given to liver&#xD;
      transplant patients by subcutaneous (under the skin) injections, over a 4 week period of&#xD;
      time, will cause an increase in the number of Treg cells in the blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A common complication of organ transplantation is 'rejection' of the transplanted organ. This&#xD;
      occurs when the body's immune system tries to attack (or reject) the transplanted organ.&#xD;
&#xD;
      Drugs known as immunosuppressants (anti-rejection medications) are prescribed for patients&#xD;
      after transplantation to prevent rejection. But, anti-rejection medications are associated&#xD;
      with significant side effects including high blood pressure, high blood sugars, and high&#xD;
      cholesterol - all of which may increase the risk of heart and vascular complications.&#xD;
      Anti-rejection medications also increase the long-term risk of some types of cancer.&#xD;
&#xD;
      Sometimes, liver transplant patients who stop taking anti-rejection medications do not&#xD;
      experience rejection of their transplanted liver and the liver keeps working. These patients&#xD;
      are said to &quot;tolerate&quot; the transplanted liver, and this condition is referred to as&#xD;
      &quot;tolerance&quot;. Doctors are working to learn more about why some liver transplant patients&#xD;
      develop tolerance after receiving a transplant, while others do not.&#xD;
&#xD;
      Studies have shown that patients who develop &quot;tolerance&quot; have an increase in a type of immune&#xD;
      cell called regulatory T-cells or &quot;Tregs&quot;. This means Tregs may be important in preventing&#xD;
      rejection of a transplanted organ.&#xD;
&#xD;
      Studies have also shown that a human cytokine (a type of protein), called interleukin-2&#xD;
      (IL-2) aids in increasing the number of Treg cells in the body, and IL-2 has been given to&#xD;
      patients to successfully treat disorders of the immune system such as graft vs host disease -&#xD;
      a serious condition sometimes seen in patients after bone marrow transplantation.&#xD;
&#xD;
      The purpose of this investigation is to study if low dose IL-2, given to liver transplant&#xD;
      patients by subcutaneous (under the skin) injections, over a 4 week period of time, will&#xD;
      cause an increase in the number of Treg cells in the blood.&#xD;
&#xD;
      In addition, investigators will learn about the kinds of side effects low dose IL-2 will&#xD;
      cause and how severe those side effects will be.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regulatory T-Cell Count</measure>
    <time_frame>12 weeks</time_frame>
    <description>Peripheral Blood Mononuclear Cell Flow Cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differential Immune Cell Count</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Peripheral Blood Mononuclear Cell Flow Cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-Cell Exhaustion Phenotyping</measure>
    <time_frame>1 Day</time_frame>
    <description>Peripheral Blood Mononuclear Cell Flow Cytometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Kidney Function Serum Panel (&gt; 1.5 x Upper Limit Normal)</measure>
    <time_frame>12 weeks</time_frame>
    <description>eGFR, creatinine, pH, electrolytes</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver Function Serum Panel (&gt; 2 x Upper Limit Normal)</measure>
    <time_frame>12 weeks</time_frame>
    <description>ALT, AST, AlkPhos, total Bilirubin</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Simple absolute counts and frequency</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.</description>
    <arm_group_label>Interleukin-2</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Aldesleukin</other_name>
    <other_name>Proleukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Adult liver transplant recipients 2-4 years post transplantation&#xD;
&#xD;
          2. Male or female adult, age 18 - 65 years&#xD;
&#xD;
          3. Stable dosage of suppressant therapy for 1 month prior to study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Recipient of multiple transplants (including solid organ, stem-cell, and bone marrow)&#xD;
&#xD;
          2. Serum liver panel (ALT, AST, Alkaline Phosphatase and Total Bilirubin) &gt; 2 x ULN,&#xD;
&#xD;
          3. Serum creatinine &gt; 1.5 x ULN,&#xD;
&#xD;
          4. eGFR of &lt; 40 ml/min,&#xD;
&#xD;
          5. Detectable hepatitis viral load,&#xD;
&#xD;
          6. Abnormal ECG with clinically significant findings per study physician's judgement,&#xD;
&#xD;
          7. Active infection,&#xD;
&#xD;
          8. Presence or history of autoimmunity disorders,&#xD;
&#xD;
          9. Evidence of allograft rejection,&#xD;
&#xD;
         10. Liver biopsy or fibroscan evidence of advanced stage liver fibrosis (&gt; Stage 2&#xD;
             Fibrosis),&#xD;
&#xD;
         11. Presence or history of cardiac or pulmonary disease,&#xD;
&#xD;
         12. Pregnant or nursing (lactating) women,&#xD;
&#xD;
         13. Health condition precludes participation in trial at study physician's judgment,&#xD;
&#xD;
         14. Inability to give consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Curry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Curry</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

